August 23, 2023 02:48 PM EDTUpdated August 25, 11:00 AM

GSK asks US patent office to refuse Moderna’s ‘Covid Mvax’ trademark registration as 'too generic'

Beth Snyder Bulik

Senior Editor

Before there were Covid-19 vaccines, there were trademarked names for Covid-19 vaccines. The pharma companies working fast and furiously on the scientific discoveries in 2020 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK asks US patent office to refuse Moderna’s ‘Covid Mvax’ trademark registration as 'too generic'

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

GSK asks US patent of­fice to refuse Mod­er­na’s ‘Covid Mvax’ trade­mark reg­is­tra­tion as 'too gener­ic'

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

GSK asks US patent office to refuse Moderna’s ‘Covid Mvax’ trademark registration as 'too generic'

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?